BioInsights - Optimizing the workflow for therapeutic viral vectors – upstream and downstream
Jul
18
2019
On demand

Optimizing the workflow for therapeutic viral vectors – upstream and downstream

Sponsor
Optimizing the workflow for therapeutic viral vectors – upstream and downstream

As an industry we can make viral vectors. Now it is time to refine processes to achieve the yield and quality needed to support research, development, and commercialization while controlling costs. Collectively, small changes in unit operations can have a big impact on developing a process that is efficient and scalable, yet flexible enough to adapt over time.

Watch this on demand webinar with Dr Spencer Hoover, Director of Process and Analytical Development – Centre for Advanced Therapeutic Cell Technologies, Centre for Commercialization of Regenerative Medicine (CCRM), Dr Lesley Chan, Senior Scientist, Vector Process Development, Bluebird Bio and Francesca Bellintani, Downstream Process Development Manager, MolMed.

  • Understand the key challenges with viral vector production and identify the major bottleneck steps
  • Find out how industry leaders are currently addressing issues with current production volumes and titers, and seeking to alleviate the capacity crunch
  • Get updated on the latest advances with stable producer cell lines and improved purification techniques
  • Gain high-level regulatory insights around viral vector bioprocessing

Spencer Hoover
Spencer Hoover
Principal at Self Employed
Lesley Chan
Lesley Chan
Senior Scientist at bluebird bio, Inc
Francesca Bellintani
Francesca Bellintani
Downstream Vector Development Manager at AGC Biologics

SPEAKERS

Spencer Hoover
Spencer Hoover
Principal at Self Employed
Lesley Chan
Lesley Chan
Senior Scientist at bluebird bio, Inc
Francesca Bellintani
Francesca Bellintani
Downstream Vector Development Manager at AGC Biologics

You might also like